Regorafenib in gastrointestinal stromal tumors

Future Oncology

Volumn 10, Issue 9, 2014, Pages 1581-1587

  Sirohi, Bhawna ^a   Philip, Deepa Susan ^a   Shrikhande, Shailesh V ^a  

^a TATA MEMORIAL HOSPITAL   (India)

Author keywords

advanced; GIST; multikinase inhibitor; regorafenib

Indexed keywords

IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR; REGORAFENIB; SUNITINIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; PYRIDINE DERIVATIVE;

ADVANCED CANCER; ARTICLE; CANCER PATIENT; COLORECTAL CANCER; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); CLINICAL TRIAL (TOPIC); GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; PHENYLUREA COMPOUNDS; PYRIDINES; TREATMENT OUTCOME;

EID: 84906557264     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.14.101     Document Type: Article

References (26)

1. Miettinen M, Lasota J. Gastrointestinal stromal tumours: pathology and prognosis at different sites. Semin. Diagn. Pathol. 23(2), 70-83 (2006
2. Hirota S, Isozaki K, Moriyama Y et al. Gain-of-function mutations of c-KIT in human gastrointestinal stromal tumors. Science 23, 279(5350), 577-80 (1998
3. Fletcher CD, Berman JJ, Corless C et al. Diagnosis of gastrointestinal stromal tumours: a consensus approach. Hum. Pathol. 33(5), 459-65 (2002
4. DeMatteo RP, Lewis JJ, Leung D et al. Two hundred gastrointestinal stromal tumours: recurrence patterns and prognostic factors for survival. Ann. Surg. 231, 51-58 (2000
5. Demetri GD, van Oosterom AT, Garrett CR et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomized controlled trial. Lancet 368, 1329-1338 (2006
6. Montemurro M, Schöffski P, Reichardt P et al. Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib. Eur. J. Cancer 45, 2293-2297 (2009).
7. Nishida T, Sawaki A, Doi T et al. Phase Iii trial of nilotinib as third-line therapy for gastrointestinal stromal tumor (GIST) patients in Japan. J. Clin. Oncol. 28(Suppl.), S15 (2010) (Abstract 10015).
8. Reichardt P, Blay JY, Gelderblom H. Phase IiiI trial of nilotinib in patients with advanced gastrointestinal stromal tumor (GIST): first results from ENEST g3. J. Clin. Oncol. 28(Suppl.), S15 (2010) (Abstract 10017
9. Demetri GD, Reichardt P, Kang Y-K et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, Phase trial. Lancet 381(9863), 295-302 (2013
10. Wilhelm SM, Dumas J, Adnane L et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int. J. Cancer 129, 245-255 (2011
11. Wilhelm SM, Carter C, Tang L et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64, 7099-7109 (2004
12. Demetri GD. Differential properties of current tyrosine kinase inhibitors in gastrointestinal stromal tumors. Semin. Oncol. 38(Suppl. 1), S10-S19 (2011
13. Carr BI, Cavallini A, Lippolis C et al. Fluoro-sorafenib (regorafenib) effects on hepatoma cells: growth inhibition, quiescence, and recovery. J. Cell. Physiol. 228(2), 292-297 (2013
14. Zopf D, Heinig R, Thierauch K-H et al. Regorafenib (BAY 73-4506): preclinical pharmacology and clinical identification and quantification of its major metabolites 17-2421. Presented at: American Association for Cancer Research 101st Annual Meeting. Washington, DC, USA, 17-21 April 2010
15. Mross K, Frost A, Steinbild S et al. A Phase dose-escalation study of regorafenib (BAY-73-4506), an inhibitor of oncogenic, angiogenic and stromal kinases in patients with advanced solid tumours. Clin. Cancer Res. 18(9), 2658-2667 (2012
16. Shimizu T, Tolcher AW, Patnaik A et al. Phase II dose-escalation study of continuously administered regorafenib (BAY 73-4506), an inhibitor of oncogenic and angiogenic kinases, in patients with advanced solid tumors. J. Clin. Oncol. 28(Suppl. 15), Abstract 3035 (2013
17. Sunakawa Y, Furuse J, Okusaka T et al. Regorafenib in Japanese patients with solid tumors: Phase II study of safety, efficacy, and pharmacokinetics. Invest. New Drugs 32(1), 104-112 (2014
18. Strumberg D, Scheulen ME, Schultheis B et al. Regorafenib (BAY 73-4506) in advanced colorectal cancer: a Phase II study. Br. J. Cancer 106, 1722-1727 (2012
19. Pantaleo MA, Landuzzi L, Nicoletti G et al. Advances in preclinical therapeutics development using small animal imaging and molecular analyses: the gastrointestinal stromal tumors model. Clin. Exp. Med. 9(3), 199-205 (2009
20. George S, Wang Q, Heinrich MC et al. Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter Phase Iii trial. J. Clin. Oncol. 30(19), 2401-2407 (2012
21. Reichardt P, Casali P, Kang YK et al. Updated results from the GRID trial-an international Phase 3, randomized, double-blind, placebo-controlled trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (im) and sunitinib (su). Presented at: Connective Tissue Oncology Society (CTOS 2012). Prague, Czech Republic, 14-17 November 2012
22. Kang YK, Ryu MH, Yoo C et al. Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, Phase 3 trial. Lancet Oncol. 14(12), 1175-1182 (2013
23. Belum VR, Wu S, Lacouture ME. Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis. Invest. New Drugs 31(4), 1078-1086 (2013
24. Montemurro M, Gelderblom H, Bitz U et al. Sorafenib as third-or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: a retrospective analysis. Eur. J. Cancer 49(5), 1027-1031 (2013
25. Park SH, Ryu MH, Ryoo BY et al. Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a Phase Iii study of Korean gastrointestinal stromal tumors study group. Invest. New Drugs 30(6), 2377-2383 (2012
26. Demetri GD, Jeffers M, Reichardt P et al. Mutational analysis of plasma DNA from patients (pts) in the Phase IiiI GRID study of regorafenib (REG) versus placebo (PL) in tyrosine kinase inhibitor (TKI)-refractory GIST: Correlating genotype with clinical outcomes. J. Clin. Oncol. 31(Suppl.) Abstract 10503 (2013).